<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799456</url>
  </required_header>
  <id_info>
    <org_study_id>GAG-BCa-001</org_study_id>
    <nct_id>NCT05799456</nct_id>
  </id_info>
  <brief_title>Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma</brief_title>
  <official_title>Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chalmers University of Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early detection of bladder cancer (BCa) is considered an effective strategy to curb mortality&#xD;
      from the disease. However, current urinary biomarkers have insufficient specificity to&#xD;
      warrant BCa screening. Urine free glycosaminoglycan profiles (or GAGomes) are promising&#xD;
      noninvasive biomarkers of cancer metabolism. In this study, samples are obtained from&#xD;
      patients with BCa and controls to compare the glycosaminoglycan profiles between groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">February 28, 2023</completion_date>
  <primary_completion_date type="Actual">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area-under-the-receiving operating characteristic (ROC)-curve (AUC) for the classification of BCa versus NED</measure>
    <time_frame>Before primary surgery for BCa; at a post-surgical follow-up visit for controls up to 5 years from primary surgery</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">106</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Bladder cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No evidence of disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Free glycosaminoglycan profiling</intervention_name>
    <description>Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.</description>
    <arm_group_label>Bladder cancer</arm_group_label>
    <arm_group_label>No evidence of disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective case-control study to compare patients elected for transurethral resection of&#xD;
        the bladder (TURB) for bladder cancer (BCa) [cases] versus patients with no evidence of&#xD;
        disease (NED) during the follow-up of previously localised BCa [controls].&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cases (Bladder cancer [BCa])&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary BCa diagnosis at cystoscopy, planned for TURB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No histopathological diagnosis of BCaTa-T4 N0-2 MX-0 after TURB&#xD;
&#xD;
        Controls (No evidence of disease [NED])&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  In follow-up with cystoscopy after treatment Ta-T3 N0-2 M0 BCa or upper tract&#xD;
             urothelial cancer no evidence of disease at cystoscopy for at least 6 months prior to&#xD;
             inclusion&#xD;
&#xD;
          -  No history of cancer except urothelial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive cytology at inclusion visit&#xD;
&#xD;
          -  Intravesical instillation therapy during 6 months prior to inclusion visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chalmers University of Technology</investigator_affiliation>
    <investigator_full_name>Jens Nielsen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

